Ruxolitinib is a JAK1 and JAK2 inhibitor, approved by the U.S. Food and Drug Administration (FDA) in November 2011, highly effective in the clinical management of myelofibrosis and associated complications (splenomegaly consequent to extramedullary hematopoiesis, cytopenias). We describe a case of Ruxolitinib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with myelofibrosis. A 74 year old woman was diagnosed with myelofibrosis in 2013 and was put on Ruxolinitib, without association of other immunosuppresive drugs. This article is protected by copyright. All rights reserved.
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with Ruxolitinib
CALZAVARA PINTON, Piergiacomo;MOGGIO, Erica;
2015-01-01
Abstract
Ruxolitinib is a JAK1 and JAK2 inhibitor, approved by the U.S. Food and Drug Administration (FDA) in November 2011, highly effective in the clinical management of myelofibrosis and associated complications (splenomegaly consequent to extramedullary hematopoiesis, cytopenias). We describe a case of Ruxolitinib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with myelofibrosis. A 74 year old woman was diagnosed with myelofibrosis in 2013 and was put on Ruxolinitib, without association of other immunosuppresive drugs. This article is protected by copyright. All rights reserved.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
